Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ENLIGHTED study aims to recruit 100 patients with low-grade UTUC in either the kidney or the ureter. The patients will be treated with Padeliporfin ImPACT in two phases, induction treatment and maintenance treatment, and will be followed up for 1-5 y...
Product Name : Padeliporfin ImPACT
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 20, 2021
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba Biotech
Details : This swiftly follows clearance of the Investigational New Drug (IND) application granted in December 2020 allowing initiation of the pivotal Phase 3 clinical trial of padeliporfin ImPACT in patients with low-grade UTUC, expected to begin enrollment in Q1...
Product Name : Padeliporfin ImPACT
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 15, 2021
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable